Ministries Announce Joint Discussion on Puberty Blocking Drug Use in Minors with Gender Dysphoria

Schillaci and Roccella Collaborating on New guidelines for Triptorelin Dysphoria

In response to growing concerns over the use of triptorelin, a puberty blocking drug, in minors with gender dysphoria, the Ministry of Health and the Ministry of Family have announced a joint discussion. Led by Ministers Orazio Schillaci and Eugenia Roccella, this initiative aims to develop new guidelines based on scientific literature and experiences from other countries that are reevaluating their positions on the issue.

The two ministries have released a joint statement summarizing their work so far on gender dysphoria and the use of blockers. This includes a hearing with scientific societies involved in the issue, as well as a request made to the National Bioethics Committee to reevaluate the use of triptorelin in cases of dysphoria in minors. Additionally, they are conducting a survey among regions regarding clinical monitoring, expenditures, and prescriptions of triptorelin for cases of dysphoria.

AIFA has also been requested to provide a report on the therapeutic indications for the drug. This collaborative effort represents a proactive approach to addressing the complex issue of gender dysphoria in minors, with a focus on evidence-based guidelines and best practices. As the table of technicians and experts continues its work to develop new specific guidelines for this important issue, stay tuned for updates.

In response to growing concerns over the use of triptorelin, a puberty blocking drug, in minors with gender dysphoria, the Ministry of Health and the Ministry of Family have announced a joint discussion. Led by Ministers Orazio Schillaci and Eugenia Roccella, this initiative aims to develop new guidelines based on scientific literature and experiences from…

Leave a Reply